Citations (18)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (3)
Frank G. Sandmann, Sarah Mostardt, Stefan K. Lhachimi & Andreas Gerber-Grote. (2018) The efficiency-frontier approach for health economic evaluation versus cost-effectiveness thresholds and internal reference pricing: combining the best of both worlds?. Expert Review of Pharmacoeconomics & Outcomes Research 18:5, pages 475-486.
Read now
Read now
Montarat Thavorncharoensap, Yot Teerawattananon, Sirin Natanant, Wantanee Kulpeng, Jomkwan Yothasamut & Pitsaphun Werayingyong. (2013) Estimating the willingness to pay for a quality-adjusted life year in Thailand: does the context of health gain matter?. ClinicoEconomics and Outcomes Research 5, pages 29-36.
Read now
Read now
Maarten J Postma, Rob PM Baltussen, Abraham M Palache & Jan C Wilschut. (2006) Further evidence for favorable cost-effectiveness of elderly influenza vaccination. Expert Review of Pharmacoeconomics & Outcomes Research 6:2, pages 215-227.
Read now
Read now
Articles from other publishers (15)
Najmeh Moradi, Arash Rashidian, Shirin Nosratnejad, Alireza Olyaeemanesh, Marzieh Zanganeh & Leila Zarei. (2019) Willingness to pay for one quality-adjusted life year in Iran. Cost Effectiveness and Resource Allocation 17:1.
Crossref
Crossref
Mike van der Have, Bas Oldenburg, Herma H. Fidder, Tim D. G. Belderbos, Peter D. Siersema & Martijn G. H. van Oijen. (2013) Optimizing Screening for Tuberculosis and Hepatitis B Prior to Starting Tumor Necrosis Factor-α Inhibitors in Crohn’s Disease. Digestive Diseases and Sciences 59:3, pages 554-563.
Crossref
Crossref
Petros Pechlivanoglou, Robin De Vries, Simon M.G.J. Daenen & Maarten J. Postma. (2011) Cost Benefit and Cost Effectiveness of Antifungal Prophylaxis in Immunocompromised Patients Treated for Haematological Malignancies. PharmacoEconomics 29:9, pages 737-751.
Crossref
Crossref
Abdulrazaq S. Al-Jazairi, Nada S. Al-Qadheeb & Aziza Ajlan. (2011) Pharmacoeconomic Analysis in Saudi Arabia: An Overdue Agenda Item for Action. Annals of Saudi Medicine 31:4, pages 335-341.
Crossref
Crossref
Tjalke A. Westra, Robin de Vries, Johannes J. Tamminga, Christophe J. Sauboin & Maarten J. Postma. (2010) Cost-effectiveness analysis of various pertussis vaccination strategies primarily aimed at protecting infants in the Netherlands. Clinical Therapeutics 32:8, pages 1479-1495.
Crossref
Crossref
Mark H. Rozenbaum, Eelko Hak, Tjip S. van der Werf & Maarten J. Postma. (2010) Results of a cohort model analysis of the cost-effectiveness of routine immunization with 13-valent pneumococcal conjugate vaccine of those aged ≥65 years in the Netherlands. Clinical Therapeutics 32:8, pages 1517-1532.
Crossref
Crossref
S. R. EARNSHAW, R. M. KLOK, S. IYER & C. MCDADE. (2010) Methylnaltrexone bromide for the treatment of opioid‐induced constipation in patients with advanced illness – a cost‐effectiveness analysis. Alimentary Pharmacology & Therapeutics 31:8, pages 911-921.
Crossref
Crossref
Mark H. Rozenbaum, Albert Jan van Hoek, Eelko Hak & Maarten J. Postma. (2010) Huge impact of assumptions on indirect effects on the cost-effectiveness of routine infant vaccination with 7-valent conjugate vaccine (Prevnar®). Vaccine 28:12, pages 2367-2369.
Crossref
Crossref
Robin de Vries, Rogier M. Klok, Jacobus R.B.J. Brouwers & Maarten J. Postma. (2009) Cost-effectiveness of a potential future Helicobacter pylori vaccine in the Netherlands: The impact of varying the discount rate for health. Vaccine 27:6, pages 846-852.
Crossref
Crossref
Robin de Vries, Jan E.A.M. van Bergen, Lolkje T.W. de Jong-van den Berg & Maarten J. Postma. (2008) Cost-Utility of Repeated Screening for Chlamydia Trachomatis. Value in Health 11:2, pages 272-274.
Crossref
Crossref
Stefan Vegter, Cornelis Boersma, Mark Rozenbaum, Bob Wilffert, GerJan Navis & Maarten J Postma. (2008) Pharmacoeconomic Evaluations of Pharmacogenetic and Genomic Screening Programmes. PharmacoEconomics 26:7, pages 569-587.
Crossref
Crossref
Robin de Vries, Simon Daenen, Keith Tolley, Axel Glasmacher, Archie Prentice, Sarah Howells, Hariette Christopherson, Lolkje T W de Jong-van den Berg & Maarten J Postma. (2008) Cost Effectiveness of Itraconazole in the Prophylaxis of Invasive Fungal Infections. PharmacoEconomics 26:1, pages 75-90.
Crossref
Crossref
Cornelis Boersma, George W. Carides, Jarir Atthobari, Adriaan A. Voors & Maarten J. Postma. (2007) An economic assessment of losartan-based versus atenolol-based therapy in patients with hypertension and left-ventricular hypertrophy: Results from the losartan intervention for endpoint reduction (LIFE) study adapted to The Netherlands. Clinical Therapeutics 29:5, pages 963-971.
Crossref
Crossref
Maarten J Postma, Annoesjka Novak, Huib W K F H Scheijbeler, Marlene Gyldmark, Marianne L L van Genugten & Jan C Wilschut. (2007) Cost Effectiveness of Oseltamivir Treatment for Patients with Influenza-Like Illness Who Are at Increased Risk for Serious Complications of Influenza. PharmacoEconomics 25:6, pages 497-509.
Crossref
Crossref
Jarir Atthobari, Folkert W. Asselbergs, Cornelis Boersma, Robin de Vries, Hans L. Hillege, Wiek H. van Gilst, Ron T. Gansevoort, Paul E. de Jong, Lolkje T.W. de Jong-van den Berg & Maarten J. Postma. (2006) Cost-effectiveness of screening for albuminuria with subsequent fosinopril treatment to prevent cardiovascular events: A pharmacoeconomic analysis linked to the prevention of renal and vascular endstage disease (PREVEND) study and the prevention of renal and vascular endstage disease intervention trial (PREVEND IT). Clinical Therapeutics 28:3, pages 432-444.
Crossref
Crossref